"004.006" . . . . . . "Bezpe\u010Dnost a \u00FA\u010Dinnost pod\u00E1v\u00E1n\u00ED kvetiapinu t\u011Bhotn\u00FDm \u017Een\u00E1m nebyla zji\u0161\u0165ov\u00E1na.\nTesty na zv\u00ED\u0159atech dosud neodhalily \u017E\u00E1dn\u00E9 \u0161kodliv\u00E9 \u00FA\u010Dinky, av\u0161ak nebyl dosud sledov\u00E1n vliv na v\u00FDvoj o\u010D\u00ED u\u00A0plodu. Seroquel PROLONG lze pod\u00E1vat v\u00A0t\u011Bhotenstv\u00ED pouze tehdy, kdy\u017E o\u010Dek\u00E1van\u00FD efekt l\u00E9\u010Dby p\u0159ev\u00E1\u017E\u00ED nad mo\u017En\u00FDmi riziky. \nU novorozenc\u016F, kte\u0159\u00ED byli b\u011Bhem t\u0159et\u00EDho trimestru t\u011Bhotenstv\u00ED vystaveni vlivu antipsychotik (v\u010Detn\u011B kvetiapinu), existuje riziko ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F v\u010Detn\u011B extrapyramidov\u00FDch p\u0159\u00EDznak\u016F a/nebo p\u0159\u00EDznak\u016F z vysazen\u00ED. Tyto p\u0159\u00EDznaky se mohou li\u0161it v d\u00E9lce trv\u00E1n\u00ED i v z\u00E1va\u017Enosti. Byly hl\u00E1\u0161eny p\u0159\u00EDpady agitovanosti, hypertonie, hypotonie, tremoru, somnolence, respira\u010Dn\u00ED t\u00EDsn\u011B nebo poruch p\u0159\u00EDjmu potravy. Proto by novorozenci m\u011Bli b\u00FDt pe\u010Dliv\u011B monitorov\u00E1ni.\n \nExistuj\u00ED publikovan\u00E9 zpr\u00E1vy o\u00A0vylu\u010Dov\u00E1n\u00ED kvetiapinu do mate\u0159sk\u00E9ho ml\u00E9ka u\u00A0lid\u00ED, ov\u0161em stupe\u0148 exkrece nebyl konzistentn\u00ED. \u017Den\u00E1m, kter\u00E9 u\u017E\u00EDvaj\u00ED p\u0159\u00EDpravek Seroquel PROLONG, se proto kojen\u00ED v\u00A0pr\u016Fb\u011Bhu l\u00E9\u010Dby nedoporu\u010Duje.\n"@cs . "4.6\tFertilita, t\u011Bhotenstv\u00ED a kojen\u00ED"@cs .